Publications

1. Candelaria PV, Nava M, Daniels-Wells TR, Penichet ML. A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma.. Cancers, 2023.
2. Daniels-Wells TR, Candelaria PV, Kranz E, Wen J, Wang L, Kamata M, Almagro JC, Martínez-Maza O, Penichet ML. Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma.. Cancers, 2023.
3. Martínez LE, Ibarrondo J, Guo Y, Penichet ML, Epeldegui M. Follicular CD8+ T Cells Are Elevated in HIV Infection and Induce PD-L1 on B Cells.. Journal of immunology (Baltimore, Md. : 1950), 2023.
4. Swain RM, Contreras L, Varela-Ramirez A, Hossain M, Das U, Valenzuela CA, Penichet ML, Dimmock JR, Aguilera RJ. Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines.. Investigational new drugs, 2022.
5. Hess JD, Macias LH, Gutierrez DA, Moran-Santibanez K, Contreras L, Medina S, Villanueva PJ, Kirken RA, Varela-Ramirez A, Penichet ML, Aguilera RJ. Identification of a Unique Cytotoxic Thieno[2,3-c]Pyrazole Derivative with Potent and Selective Anticancer Effects In Vitro.. Biology, 2022.
6. Candelaria PV, Nava M, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2022.
7. Hickerson BT, Daniels-Wells TR, Payes C, Clark LE, Candelaria PV, Bailey KW, Sefing EJ, Zink S, Ziegenbein J, Abraham J, Helguera G, Penichet ML, Gowen BB. Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections.. Nature communications, 2022.
8. Markov SD, Caffrey TC, O'Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, Singh PK, Madiyalakan R, Daniels-Wells TR, Penichet ML, Nicodemus CF, Poole JA, Jaffee EM, Hollingsworth MA, Mehla K. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.. Molecular cancer therapeutics, 2021.
9. Martínez LE, Daniels-Wells TR, Guo Y, Magpantay LI, Candelaria PV, Penichet ML, Martínez-Maza O, Epeldegui M. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV+ Human Primary B-cells.. Molecular cancer therapeutics, 2021.
10. Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.. Frontiers in immunology, 2021.
11. Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY. Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.. Nature communications, 2020.
12. Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.. Oncoimmunology, 2020.
13. Hickerson BT, Sefing EJ, Bailey KW, Van Wettere AJ, Penichet ML, Gowen BB. Type I interferon underlies severe disease associated with Junín virus infection in mice.. eLife, 2020.
14. Daniels-Wells TR, Candelaria PV, Leoh LS, Nava M, Martínez-Maza O, Penichet ML. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2020.
15. Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY. Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.. Nature communications, 2020.
16. Epeldegui M, Conti DV, Guo Y, Cozen W, Penichet ML, Martínez-Maza O. Author Correction: Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.. Scientific reports, 2020.
17. Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, Klymyshyn D, Tourtellotte WG, Israel LL, Braubach O, Ljubimov VA, Mashouf LA, Ramesh A, Grodzinski ZB, Penichet ML, Black KL, Holler E, Sun T, Ding H, Ljubimov AV, Ljubimova JY. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.. Nature communications, 2019.
18. Epeldegui M, Conti DV, Guo Y, Cozen W, Penichet ML, Martínez-Maza O. Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.. Scientific reports, 2019.
19. Luria-Pérez R, Candelaria PV, Daniels-Wells TR, Rodríguez JA, Helguera G, Penichet ML. Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.. Cytokine, 2019.
20. Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, Hartmann K, Josephs DH, Levi-Schaffer F, Penichet ML, O'Mahony L, Poli A, Redegeld FA, Roth-Walter F, Turner MC, Vangelista L, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper.. Allergy, 2019.
21. Plotkin JD, Elias MG, Fereydouni M, Daniels-Wells TR, Dellinger AL, Penichet ML, Kepley CL. Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.. Frontiers in immunology, 2019.
22. Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, Rudnick JD, Hu J, Grodzinski ZB, Rekechenetskiy A, Falahatian V, Lyubimov AV, Chen YL, Leoh LS, Daniels-Wells TR, Penichet ML, Holler E, Ljubimov AV, Black KL, Ljubimova JY. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.. Cancer research, 2019.
23. Leoh LS, Kim YK, Candelaria PV, Martínez-Maza O, Daniels-Wells TR, Penichet ML. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.. Journal of immunology (Baltimore, Md. : 1950), 2018.
24. Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF. Virus-like particle display of HER2 induces potent anti-cancer responses.. Oncoimmunology, 2018.
25. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.. Frontiers in immunology, 2018.
26. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Corrigendum to "Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1" [Mol. Immunol. 67 (2015) 407-415].. Molecular immunology, 2016.
27. Shi Y, Daniels-Wells TR, Frost P, Lee J, Finn RS, Bardeleben C, Penichet ML, Jung ME, Gera J, Lichtenstein A. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.. Cancer research, 2016.
28. Daniels-Wells TR, Penichet ML. Transferrin receptor 1: a target for antibody-mediated cancer therapy.. Immunotherapy, 2016.
29. Koru-Sengul T, Santander AM, Miao F, Sanchez LG, Jorda M, Glück S, Ince TA, Nadji M, Chen Z, Penichet ML, Cleary MP, Torroella-Kouri M. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians.. Breast cancer research and treatment, 2016.
30. Daniels-Wells TR, Widney DP, Leoh LS, Martínez-Maza O, Penichet ML. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2015.
31. Leoh LS, Daniels-Wells TR, Martínez-Maza O, Penichet ML. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.. Molecular immunology, 2015.
32. Cornford EM, Hyman S, Cornford ME, Chytrova G, Rhee J, Suzuki T, Yamagata T, Yamakawa K, Penichet ML, Pardridge WM. Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes.. Journal of drug targeting, 2015.
33. Leoh LS, Daniels-Wells TR, Penichet ML. IgE immunotherapy against cancer.. Current topics in microbiology and immunology, 2015.
34. De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.. Breast cancer research : BCR, 2014.
35. Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.. Molecular cancer therapeutics, 2014.
36. Leoh LS, Morizono K, Kershaw KM, Chen IS, Penichet ML, Daniels-Wells TR. Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.. The journal of gene medicine, 2014.
37. Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet ML, Martinez-Maza O. Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7.. PloS one, 2013.
38. Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.. Journal of controlled release : official journal of the Controlled Release Society, 2013.
39. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.. BMC cancer, 2013.
40. VanderWall K, Daniels-Wells TR, Penichet M, Lichtenstein A. Iron in multiple myeloma.. Critical reviews in oncogenesis, 2013.
41. Daniels-Wells TR, Helguera G, Rodríguez JA, Leoh LS, Erb MA, Diamante G, Casero D, Pellegrini M, Martínez-Maza O, Penichet ML. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1.. Toxicology in vitro : an international journal published in association with BIBRA, 2012.
42. Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer.. Breast cancer research and treatment, 2012.
43. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target.. Clinical lymphoma, myeloma & leukemia, 2012.
44. Helguera G, Jemielity S, Abraham J, Cordo SM, Martinez MG, Rodríguez JA, Bregni C, Wang JJ, Farzan M, Penichet ML, Candurra NA, Choe H. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses.. Journal of virology, 2012.
45. Daniels TR, Martínez-Maza O, Penichet ML. Animal models for IgE-meditated cancer immunotherapy.. Cancer immunology, immunotherapy : CII, 2011.
46. Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.. Cancer immunology, immunotherapy : CII, 2011.
47. Hahn T, Bradley-Dunlop DJ, Hurley LH, Von-Hoff D, Gately S, Mary DL, Lu H, Penichet ML, Besselsen DG, Cole BB, Meeuwsen T, Walker E, Akporiaye ET. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.. BMC cancer, 2011.
48. Rodríguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, Martínez-Maza O, Charles AC, Pellegrini M, Helguera G, Penichet ML. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.. Leukemia & lymphoma, 2011.
49. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer.. Biochimica et biophysica acta, 2011.
50. Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2011.
51. Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.. Forum on immunopathological diseases and therapeutics, 2011.
52. Helguera G, Rodríguez JA, Luria-Pérez R, Henery S, Catterton P, Bregni C, George TC, Martínez-Maza O, Penichet ML. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry.. Journal of immunological methods, 2011.
53. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, Espinoza A, Suhane S, Riley M, Gates M, Patil R, Penichet ML, Ljubimov AV, Black KL, Holler E, Ljubimova JY. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.. Cancer research, 2011.
54. Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet ML, Montano RF. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.. Molecular cancer therapeutics, 2010.
55. Bermudez-Fajardo A, Stark AK, El-Kadri R, Penichet ML, Hölzle K, Wittenbrink MM, Hölzle L, Oviedo-Orta E. The effect of Chlamydophila pneumoniae Major Outer Membrane Protein (MOMP) on macrophage and T cell-mediated immune responses.. Immunobiology, 2010.
56. Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.. International journal of oncology, 2010.
57. Rodríguez JA, Lopez MA, Thayer MC, Zhao Y, Oberholzer M, Chang DD, Kisalu NK, Penichet ML, Helguera G, Bruinsma R, Hill KL, Miao J. Propulsion of African trypanosomes is driven by bihelical waves with alternating chirality separated by kinks.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
58. Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet ML, Chen IS. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.. The journal of gene medicine, 2009.
59. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.. Breast cancer research : BCR, 2009.
60. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.. Cancer immunology, immunotherapy : CII, 2008.
61. Montano RF, Penichet ML, Blackall DP, Morrison SL, Chintalacharuvu KR. Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.. Journal of immunological methods, 2008.
62. Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy.. Expert opinion on biological therapy, 2008.
63. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.. Journal of immunology (Baltimore, Md. : 1950), 2008.
64. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.. Molecular cancer therapeutics, 2008.
65. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.. Clinical & developmental immunology, 2008.
66. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells.. Molecular cancer therapeutics, 2007.
67. Rodríguez JA, Helguera G, Daniels TR, Neacato II, López-Valdés HE, Charles AC, Penichet ML. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.. Journal of controlled release : official journal of the Controlled Release Society, 2007.
68. Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, Ding H, Holler E, Black KL, Ljubimova JY. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).. Journal of controlled release : official journal of the Controlled Release Society, 2007.
69. Helguera G, Rodríguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.. Cancer immunology, immunotherapy : CII, 2007.
70. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma.. Blood, 2007.
71. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.. Clinical immunology (Orlando, Fla.), 2006.
72. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.. Clinical immunology (Orlando, Fla.), 2006.
73. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.. Blood, 2006.
74. Helguera G, Rodríguez JA, Penichet ML. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.. Molecular cancer therapeutics, 2006.
75. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.. Molecular immunology, 2006.
76. Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.. Vaccine, 2005.
77. Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.. Vaccine, 2005.
78. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.. Molecular cancer therapeutics, 2005.
79. Helguera G, Penichet ML. Antibody-cytokine fusion proteins for the therapy of cancer.. Methods in molecular medicine, 2005.
80. Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.. Biomolecular engineering, 2004.
81. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.. Vaccine, 2003.
82. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.. Proceedings of the National Academy of Sciences of the United States of America, 2002.
83. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. Myeloma expression systems.. Journal of immunological methods, 2002.